This is a Validated Antibody Database (VAD) review about human LAG3, based on 28 published articles (read how Labome selects the articles), using LAG3 antibody in all methods. It is aimed to help Labome visitors find the most suited LAG3 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
LAG3 synonym: CD223

BioLegend
mouse monoclonal (11C3C65)
  • flow cytometry; human; 1:100; loading ...; fig e4h
BioLegend LAG3 antibody (Biolegend, 369320) was used in flow cytometry on human samples at 1:100 (fig e4h). Nat Med (2021) ncbi
mouse monoclonal (11C3C65)
  • other; mouse
BioLegend LAG3 antibody (BioLegend, 11C3C65) was used in other on mouse samples . Nat Commun (2020) ncbi
mouse monoclonal (11C3C65)
  • flow cytometry; human; loading ...; fig 5a
BioLegend LAG3 antibody (BioLegend, 369308) was used in flow cytometry on human samples (fig 5a). elife (2020) ncbi
mouse monoclonal (7H2C65)
  • flow cytometry; human; loading ...; fig 6b, 6c
BioLegend LAG3 antibody (BioLegend, 7H2C65) was used in flow cytometry on human samples (fig 6b, 6c). Oncoimmunology (2020) ncbi
mouse monoclonal (11C3C65)
  • flow cytometry; human; fig s6b
BioLegend LAG3 antibody (Biolegend, 369308) was used in flow cytometry on human samples (fig s6b). Nat Commun (2019) ncbi
mouse monoclonal (11C3C65)
  • flow cytometry; mouse; loading ...; fig 5b
BioLegend LAG3 antibody (Biolegend, 369312) was used in flow cytometry on mouse samples (fig 5b). J Immunother Cancer (2019) ncbi
mouse monoclonal (11C3C65)
  • flow cytometry; mouse; loading ...; fig ex2g
BioLegend LAG3 antibody (Biolegend, 11C3C65) was used in flow cytometry on mouse samples (fig ex2g). Nature (2019) ncbi
Invitrogen
mouse monoclonal (3DS223H)
  • flow cytometry; mouse; 1:1000; loading ...
Invitrogen LAG3 antibody (Thermo Fisher Scientific, 12-2239-42) was used in flow cytometry on mouse samples at 1:1000. Cell Rep Med (2021) ncbi
mouse monoclonal (3DS223H)
  • flow cytometry; human; loading ...; fig s9b
Invitrogen LAG3 antibody (eBioscience, 12-2239-42) was used in flow cytometry on human samples (fig s9b). Science (2021) ncbi
mouse monoclonal (3DS223H)
  • flow cytometry; human; fig 1b
Invitrogen LAG3 antibody (eBioscience, 3DS223H) was used in flow cytometry on human samples (fig 1b). Nature (2019) ncbi
mouse monoclonal (3DS223H)
  • flow cytometry; human; loading ...; fig 5a
Invitrogen LAG3 antibody (eBioscience, 3DS223H) was used in flow cytometry on human samples (fig 5a). Front Immunol (2019) ncbi
mouse monoclonal (3DS223H)
  • flow cytometry; human; loading ...; fig s3a
Invitrogen LAG3 antibody (eBioscience, 3DS223H) was used in flow cytometry on human samples (fig s3a). Cancer (2019) ncbi
mouse monoclonal (3DS223H)
  • flow cytometry; human; 1:100; loading ...
Invitrogen LAG3 antibody (eBioscience, 3DS223H) was used in flow cytometry on human samples at 1:100. Nature (2018) ncbi
mouse monoclonal (3DS223H)
  • flow cytometry; human; loading ...
In order to assess the effects of targeting the chimeric antigen receptors to the TRAC locus, Invitrogen LAG3 antibody (eBiosciences, 46-2239-42) was used in flow cytometry on human samples . Nature (2017) ncbi
mouse monoclonal (3DS223H)
  • flow cytometry; human; fig 3c
In order to assess the impact of neoantigen intratumor heterogeneity on antitumor immunity, Invitrogen LAG3 antibody (eBioscience, 3DS223H) was used in flow cytometry on human samples (fig 3c). Science (2016) ncbi
mouse monoclonal (3DS223H)
  • flow cytometry; human; fig 6
Invitrogen LAG3 antibody (eBioscience, 17-2239) was used in flow cytometry on human samples (fig 6). Nat Commun (2015) ncbi
Enzo Life Sciences
mouse monoclonal (17B4)
  • immunohistochemistry - frozen section; human; 1:50; fig 2
In order to investigate factors that regulate delayed-type hypersensitivity, Enzo Life Sciences LAG3 antibody (Enzo Life Sciences, 17B4) was used in immunohistochemistry - frozen section on human samples at 1:50 (fig 2). F1000Res (2015) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human
In order to investigate the primary inflammatory and regulatory T cell responses induced by BCG vaccination in adults, Enzo Life Sciences LAG3 antibody (Enzo Life Sciences, clone 17B4) was used in flow cytometry on human samples . Clin Vaccine Immunol (2015) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human; fig 1
Enzo Life Sciences LAG3 antibody (Enzo Life sciences, 17B4) was used in flow cytometry on human samples (fig 1). Retrovirology (2015) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human; loading ...; fig 1
In order to investigate the role of granzyme B in T regulatory cell resistance, Enzo Life Sciences LAG3 antibody (Enzo Life Sciences, 17B4) was used in flow cytometry on human samples (fig 1). J Immunol (2015) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human
Enzo Life Sciences LAG3 antibody (Enzo Life Sciences, 17B4) was used in flow cytometry on human samples . J Immunol (2015) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human
Enzo Life Sciences LAG3 antibody (Enzo Life Sciences, 17B4) was used in flow cytometry on human samples . Am J Reprod Immunol (2014) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human; 1:100
Enzo Life Sciences LAG3 antibody (Enzo Life Sciences, 17B4) was used in flow cytometry on human samples at 1:100. J Clin Invest (2014) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human
Enzo Life Sciences LAG3 antibody (Enzo Life Sciences, 17B4) was used in flow cytometry on human samples . J Hepatol (2014) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human
Enzo Life Sciences LAG3 antibody (Alexis Enzo Life Sciences, 17B4) was used in flow cytometry on human samples . J Immunol (2013) ncbi
mouse monoclonal (17B4)
  • flow cytometry; human
Enzo Life Sciences LAG3 antibody (Enzo Life Sciences, 17B4) was used in flow cytometry on human samples . Clin Cancer Res (2012) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D2G4O™)
  • immunocytochemistry; human; 1:500; fig 4a
  • western blot; human; loading ...; fig 1c, 1h
Cell Signaling Technology LAG3 antibody (Cell signaling, 15372) was used in immunocytochemistry on human samples at 1:500 (fig 4a) and in western blot on human samples (fig 1c, 1h). EMBO Mol Med (2021) ncbi
Adipogen
  • flow cytometry; human; fig 3
Adipogen LAG3 antibody (Adipogen, AG-20B-0012F) was used in flow cytometry on human samples (fig 3). Oncoimmunology (2016) ncbi
Articles Reviewed
  1. Spiegel J, Patel S, Muffly L, Hossain N, Oak J, Baird J, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med. 2021;27:1419-1431 pubmed publisher
  2. Emmenegger M, De Cecco E, Hruska Plochan M, Eninger T, Schneider M, Barth M, et al. LAG3 is not expressed in human and murine neurons and does not modulate α-synucleinopathies. EMBO Mol Med. 2021;13:e14745 pubmed publisher
  3. Li N, Torres M, Spetz M, Wang R, Peng L, Tian M, et al. CAR T cells targeting tumor-associated exons of glypican 2 regress neuroblastoma in mice. Cell Rep Med. 2021;2:100297 pubmed publisher
  4. Weber E, Parker K, Sotillo E, Lynn R, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021;372: pubmed publisher
  5. Tseng H, Xiong W, Badeti S, Yang Y, Ma M, Liu T, et al. Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma. Nat Commun. 2020;11:4810 pubmed publisher
  6. Bhattacharya P, Ellegård R, Khalid M, Svanberg C, Govender M, Keita A, et al. Complement opsonization of HIV affects primary infection of human colorectal mucosa and subsequent activation of T cells. elife. 2020;9: pubmed publisher
  7. Seitz C, Schroeder S, Knopf P, Krahl A, Hau J, Schleicher S, et al. GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells. Oncoimmunology. 2020;9:1683345 pubmed publisher
  8. Lynn R, Weber E, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature. 2019;576:293-300 pubmed publisher
  9. Zou F, Lu L, Liu J, Xia B, Zhang W, Hu Q, et al. Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56. Nat Commun. 2019;10:4109 pubmed publisher
  10. Wei J, Luo C, Wang Y, Guo Y, Dai H, Tong C, et al. PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity. J Immunother Cancer. 2019;7:209 pubmed publisher
  11. Lim S, Kim J, Jeon S, Shin M, Kwon J, Kim T, et al. Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019;10:496 pubmed publisher
  12. Hamieh M, Dobrin A, Cabriolu A, van der Stegen S, Giavridis T, Mansilla Soto J, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568:112-116 pubmed publisher
  13. Williams P, Basu S, Garcia Manero G, Hourigan C, Oetjen K, Cortes J, et al. The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer. 2019;125:1470-1481 pubmed publisher
  14. Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605-609 pubmed publisher
  15. Eyquem J, Mansilla Soto J, Giavridis T, van der Stegen S, Hamieh M, Cunanan K, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113-117 pubmed publisher
  16. Franzese O, Palermo B, Di Donna C, Sperduti I, Ferraresi V, Stabile H, et al. Polyfunctional Melan-A-specific tumor-reactive CD8(+) T cells elicited by dacarbazine treatment before peptide-vaccination depends on AKT activation sustained by ICOS. Oncoimmunology. 2016;5:e1114203 pubmed publisher
  17. McGranahan N, Furness A, Rosenthal R, Ramskov S, Lyngaa R, Saini S, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463-9 pubmed publisher
  18. Miles B, Miller S, Folkvord J, Kimball A, Chamanian M, Meditz A, et al. Follicular regulatory T cells impair follicular T helper cells in HIV and SIV infection. Nat Commun. 2015;6:8608 pubmed publisher
  19. Gulati N, Suárez Fariñas M, Correa Da Rosa J, Krueger J. Psoriasis is characterized by deficient negative immune regulation compared to transient delayed-type hypersensitivity reactions. F1000Res. 2015;4:149 pubmed publisher
  20. Boer M, Prins C, van Meijgaarden K, van Dissel J, Ottenhoff T, Joosten S. Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in Adults. Clin Vaccine Immunol. 2015;22:778-88 pubmed publisher
  21. Juno J, Stalker A, Waruk J, Oyugi J, Kimani M, Plummer F, et al. Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment. Retrovirology. 2015;12:17 pubmed publisher
  22. Bhela S, Kempsell C, Manohar M, Dominguez Villar M, Griffin R, Bhatt P, et al. Nonapoptotic and extracellular activity of granzyme B mediates resistance to regulatory T cell (Treg) suppression by HLA-DR-CD25hiCD127lo Tregs in multiple sclerosis and in response to IL-6. J Immunol. 2015;194:2180-9 pubmed publisher
  23. Hatano R, Ohnuma K, Otsuka H, Komiya E, Taki I, Iwata S, et al. CD26-mediated induction of EGR2 and IL-10 as potential regulatory mechanism for CD26 costimulatory pathway. J Immunol. 2015;194:960-72 pubmed publisher
  24. Juno J, Lajoie J, Stalker A, Oyugi J, Kimani M, Kimani J, et al. Enrichment of LAG-3, but not PD-1, on double negative T cells at the female genital tract. Am J Reprod Immunol. 2014;72:534-40 pubmed publisher
  25. Gros A, Robbins P, Yao X, Li Y, Turcotte S, Tran E, et al. PD-1 identifies the patient-specific CD8? tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014;124:2246-59 pubmed publisher
  26. Tan A, Hoang L, Chin D, Rasmussen E, Lopatin U, Hart S, et al. Reduction of HBV replication prolongs the early immunological response to IFN? therapy. J Hepatol. 2014;60:54-61 pubmed publisher
  27. Sumitomo S, Fujio K, Okamura T, Morita K, Ishigaki K, Suzukawa K, et al. Transcription factor early growth response 3 is associated with the TGF-?1 expression and the regulatory activity of CD4-positive T cells in vivo. J Immunol. 2013;191:2351-9 pubmed publisher
  28. Radvanyi L, Bernatchez C, Zhang M, Fox P, Miller P, Chacon J, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012;18:6758-70 pubmed publisher